Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the alzheimer’s disease diagnostic market size evolved in recent years?

In the past few years, there has been a swift expansion in the market size of Alzheimer’s disease diagnosis. The market worth, which stands at $6.56 billion in 2024, is projected to escalate to $7.28 billion in 2025, following a consistent compound annual growth rate (CAGR) of 11%. This historical augmentation can be credited to a heightened incidence of Alzheimer’s disease and dementia, mounting cognizance of the significance of pre-emptive diagnosis for superior disease management, advancements in imaging technologies like MRI and PET scans. There is also an upsurge in investment in the research and development sector related to neurodegenerative diseases along with government initiatives and funding aimed at Alzheimer’s research and diagnostic procedures.

What are the predictions for the alzheimer’s disease diagnostic market size in the coming years?

Over the next several years, the diagnostic market for Alzheimer’s disease is projected to experience significant growth, with it expanding to $10.91 billion in 2029 and a compound annual growth rate (CAGR) of 10.7%. This forecasted growth can be linked to the creation of blood-based biomarkers for non-invasive diagnosis, increasing demand for personalized and precision medicine, the use of AI and machine learning in early detection tools, the increased uptake of digital healthcare technology for remote diagnosis and monitoring, and improvements in healthcare infrastructure in emerging markets for better accessibility. Major trends anticipated during this forecast period include the rising use of multi-modal diagnostic techniques which combines imaging, biomarkers and cognitive tests, a growing emphasis on point-of-care diagnostic solutions for quicker outcomes, the creation of wearable devices that offer continuous monitoring of cognitive health, growing partnerships between biotech firms and research institutions for innovative solutions, and an increase in direct-to-consumer genetic testing for Alzheimer’s risk evaluation.

Get your alzheimer’s disease diagnostic market report here!

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What key factors are fueling the growth of the alzheimer’s disease diagnostic market?

The surge in chronic illnesses is likely to stimulate the expansion of the alzheimer’s disease diagnostic market. Chronic disease refers to any health issue that lasts for over three months. The escalation in chronic diseases is attributed to several interconnected factors including lifestyle choices, environmental factors, genetic predisposition, and socioeconomic conditions. Possessing chronic conditions like cardiovascular issues, diabetes, and high blood pressure heightens the risk of developing Alzheimer’s disease and other types of dementia. For example, a report released by the American Heart Association Inc., a US-based volunteer organization, in January 2022 indicated that brain disorders are projected to rise to 9.3 million in the US by 2060. At present, this number is on the rise in the US, and globally, one in every six people suffers from a brain disease. By 2021, it is anticipated that 1 billion individuals globally will be suffering from brain disorders. Thus, the surge in chronic diseases is predicted to fuel the growth of the alzheimer’s disease diagnostic market.

How is the global alzheimer’s disease diagnostic market divided into key segments?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

Who are the key firms paving the way for growth in the alzheimer’s disease diagnostic market?

Major companies operating in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation

What emerging trends are influencing the growth of the alzheimer’s disease diagnostic market?

Leading organizations in the Alzheimer’s disease diagnostic market are centering their efforts on the progression of blood-based biomarker tests. These advancements aim to streamline the diagnosis procedure for Alzheimer’s disease, decreasing the necessity for more invasive procedures and enhancing patients’ ability to access treatment promptly. In an exemplification of this, Quanterix – a biotechnology research entity based in the US, unveiled the LucentAD p-Tau 217 test in October 2023. This serves as a biomarker for Alzheimer’s pathology that exhibits clinical sensitivity and specificity in blood. Traditional methods for detecting cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar puncture, are not only expensive and invasive but also limited in availability. However, Quanterix’s ultra-sensitive SimoaÒ technology merges with J&J Innovative Medicine’s thoroughly examined p-Tau 217 antibodies, creating an exceedingly accurate solution that simplifies the process.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093

What regions are contributing significantly to the growth of the alzheimer’s disease diagnostic market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Cyclic Heavy Menstrual Bleeding Global Market Report 2025

https://thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: